H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

This trial is testing a new drug called H002 in people with non-small cell lung cancer (NSCLC) that has a specific genetic mutation called EGFR — which makes cancer cells grow out of control. H002 targets cells with this mutation to stop their growth. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic NSCLC confirmed by biopsy - Your cancer has an EGFR mutation (such as Del19 or L858R, or specifically the C797S mutation for Part B) - You have progressed on prior EGFR-targeted therapy - You are in good physical condition and have adequate organ function **You may NOT be eligible if...** - Your cancer does not have an EGFR mutation - You have active or untreated brain metastases - You have had certain specific prior treatments that overlap with this drug - You are pregnant or breastfeeding - You have serious heart rhythm problems or significant organ dysfunction Talk to your doctor to see if this trial is right for you.